Qiagen begins consolidating Maryland operations at Germantown headquarters


Qiagen will consolidate the majority of its Maryland operations at the company's U.S. headquarters in Germantown. (Courtesy of Qiagen/Courtesy of Qiagen)

Biotechnology company Qiagen plans to begin moving 250 employees and manufacturing operations from an office in Gaithersburg to the company’s headquarters in Germantown as part of a years-long plan to consolidate its business operations in Maryland.

The move comes nearly four years after the company broke ground on a 47,000 square-foot manufacturing facility at its headquarters in upper Montgomery County. The firm also expanded its cafeteria and made other improvements to accommodate more employees.

That facility was approved by the FDA earlier this week to become the manufacturing site for Qiagen’s widely used diagnostic assay that tests patients for several forms of the human papillomavirus, or HPV, which can lead to cervical cancer in certain instances.

Sean Augerson, the global vice president of supply chain management, said the company’s headcount will not be reduced as it consolidates into the headquarters. The company counts 550 employees in Maryland, according to a news release.

About 110 of those workers are based at a site in Frederick, which the company will not fold into the Germantown headquarters at this time, Augerson said. That location focuses on research, development and manufacturing of molecular testing products.

Qiagen, which has its corporate headquarters in Germany, also pledged Wednesday to funnel another $10 million into expansion efforts in Germantown and Frederick, bringing its total investment in Maryland to $50 million, according to a news release.

The move is expected to be complete by early 2015. Qiagen’s lease on the Gaithersburg office ends in 2016, Augerson said.

Follow reporter Steven Overly on Twitter: @StevenOverly

Steven Overly covers the business of technology, biotechnology and venture capital in the Washington region for The Washington Post and its weekly Capital Business publication. In that capacity, he has written about start-up struggles, investment trends and major drug discoveries.
Comments
Show Comments
Most Read Business